Ariel Precision Medicine
Pittsburgh, US · Founded 2013 · 4 known investors
Find your way into Ariel Precision Medicine
879 people in our graph share verified history with the Ariel Precision Medicine team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Jessica Gibson · together at Stanford University (overlapped)
×6knows the team · via Stanford University
knows the team · via The Ohio State University
×2knows the team · via University of Pittsburgh
knows the team · via Liberty University
knows the team · via University of Pittsburgh Medical Center
Ariel Precision Medicine offers an AI-driven platform that integrates genomic and clinical data (including EHR/EMR records, lab results, and scientific literature) to produce peer-reviewed, evidence-based reports. It serves clinicians diagnosing complex diseases and therapeutics developers seeking target discovery and patient stratification.
Founders & leadership
Ariel Precision Medicine was founded in 2013 by Jessica Gibson and David Whitcomb.
JG
Jessica GibsoninCo-founderJessica Gibson is an executive officer and director at Ariel Precision Medicine, which develops AI-enabled technology for precision medicine and chronic disease management.
DW
David WhitcombinCo-founderDavid Whitcomb holds research and clinical appointments at the University of Pittsburgh and UPMC, where he directs the Precision Medicine Service. His work has focused on pancreatic disease genetics and molecular pathology, identifying genetic variants associated with pancreatitis and pancreatic disease.
JM
John MooreExecutive
Board
SD
MD
Mary Del BradyBoard director
DS
David SmithBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$5.4M disclosed across 2 rounds · 2016–2019
▶$5.3MraisedJul 2019 · 20 investors · BiotechnologyRule 506(b)
▶$5.3MraisedJul 2019 · 20 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David WhitcombDirector
- Hank SaffersteinDirector
- Jessica GibsonExecutive Officer, Director
- Christopher MoehleDirector
- David SmithDirector
- John T.B. MooreExecutive Officer
- Offering amount
- $8.8M
- Amount sold
- $5.3M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$125KraisedMay 2016 · 3 investors · BiotechnologyRule 506(b)
▶$125KraisedMay 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jessica GibsonExecutive Officer, Director
- David WhitcombDirector
- Stephan DietrichDirector
- Mary Del BradyExecutive Officer, Director
- John MooreExecutive Officer
- David SmithDirector
- Offering amount
- $780K
- Amount sold
- $125K
- First sale
- May 2016
- Incorporated
- Limited Liability Company, Pennsylvania, 2013
- Federal exemptions
- 04, 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Ariel Precision Medicine do?
- Ariel Precision Medicine offers an AI-driven platform that integrates genomic and clinical data (including EHR/EMR records, lab results, and scientific literature) to produce peer-reviewed, evidence-based reports. It serves clinicians diagnosing complex diseases and therapeutics developers seeking target discovery and patient stratification.
- Who founded Ariel Precision Medicine?
- Ariel Precision Medicine was founded by Jessica Gibson, David Whitcomb in 2013.
- Who are Ariel Precision Medicine's investors?
- Ariel Precision Medicine's investors include Creative Destruction Lab (CDL), The Robotics Hub, Lead Edge Capital, Robotics Hub.
- How much funding has Ariel Precision Medicine raised?
- Ariel Precision Medicine has disclosed $5.4M raised across 2 rounds.
- Where is Ariel Precision Medicine headquartered?
- Ariel Precision Medicine is headquartered in Pittsburgh, US.